These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 7705462)

  • 1. Dexniguldipine-HCl is a potent allosteric inhibitor of [3H]vinblastine binding to P-glycoprotein of CCRF ADR 5000 cells.
    Malkhandi J; Ferry DR; Boer R; Gekeler V; Ise W; Kerr DJ
    Eur J Pharmacol; 1994 Dec; 288(1):105-14. PubMed ID: 7705462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allosteric regulation of [3H]vinblastine binding to P-glycoprotein of MCF-7 ADR cells by dexniguldipine.
    Ferry DR; Malkhandi PJ; Russell MA; Kerr DJ
    Biochem Pharmacol; 1995 Jun; 49(12):1851-61. PubMed ID: 7598747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P-glycoprotein possesses a 1,4-dihydropyridine-selective drug acceptor site which is alloserically coupled to a vinca-alkaloid-selective binding site.
    Ferry DR; Russell MA; Cullen MH
    Biochem Biophys Res Commun; 1992 Oct; 188(1):440-5. PubMed ID: 1358068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Localization of the 1,4-dihydropyridine drug acceptor of P-glycoprotein to a cytoplasmic domain using a permanently charged derivative N-methyl dexniguldipine.
    Ferry D; Boer R; Callaghan R; Ulrich WR
    Int J Clin Pharmacol Ther; 2000 Mar; 38(3):130-40. PubMed ID: 10739116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents.
    Pascaud C; Garrigos M; Orlowski S
    Biochem J; 1998 Jul; 333 ( Pt 2)(Pt 2):351-8. PubMed ID: 9657975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of action of dexniguldipine-HCl (B8509-035), a new potent modulator of multidrug resistance.
    Hofmann J; Gekeler V; Ise W; Noller A; Mitterdorfer J; Hofer S; Utz I; Gotwald M; Boer R; Glossmann H
    Biochem Pharmacol; 1995 Mar; 49(5):603-9. PubMed ID: 7887974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B9209-005, an azido derivative of the chemosensitizer dexniguldipine-HCl, photolabels P-glycoprotein.
    Borchers C; Ulrich WR; Klemm K; Ise W; Gekeler V; Haas S; Schödl A; Conrad J; Przybylski M; Boer R
    Mol Pharmacol; 1995 Jul; 48(1):21-9. PubMed ID: 7623771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the dexniguldipine binding site in the multidrug resistance-related transport protein P-glycoprotein by photoaffinity labeling and mass spectrometry.
    Borchers C; Boer R; Klemm K; Figala V; Denzinger T; Ulrich WR; Haas S; Ise W; Gekeler V; Przybylski M
    Mol Pharmacol; 2002 Jun; 61(6):1366-76. PubMed ID: 12021398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein.
    Höllt V; Kouba M; Dietel M; Vogt G
    Biochem Pharmacol; 1992 Jun; 43(12):2601-8. PubMed ID: 1352973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary combined resistance to the multidrug-resistance-reversing activity of cyclosporin A in the cell line F4-6RADR-CsA.
    Dietel M; Herzig I; Reymann A; Brandt I; Schaefer B; Bunge A; Heidebrecht HJ; Seidel A
    J Cancer Res Clin Oncol; 1994; 120(5):263-71. PubMed ID: 7907333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP.
    Germann UA; Ford PJ; Shlyakhter D; Mason VS; Harding MW
    Anticancer Drugs; 1997 Feb; 8(2):141-55. PubMed ID: 9073310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agents which reverse multidrug-resistance are inhibitors of [3H]vinblastine transport by isolated vesicles.
    Horio M; Lovelace E; Pastan I; Gottesman MM
    Biochim Biophys Acta; 1991 Jan; 1061(1):106-10. PubMed ID: 1671642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells.
    Budworth J; Davies R; Malkhandi J; Gant TW; Ferry DR; Gescher A
    Br J Cancer; 1996 May; 73(9):1063-8. PubMed ID: 8624264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of cytostatics and chemosensitizers with the dexniguldipine binding site on P-glycoprotein.
    Boer R; Ulrich WR; Haas S; Borchers C; Gekeler V; Boss H; Przybylski M; Schödl A
    Eur J Pharmacol; 1996 Jan; 295(2-3):253-60. PubMed ID: 8720592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative.
    Dale IL; Tuffley W; Callaghan R; Holmes JA; Martin K; Luscombe M; Mistry P; Ryder H; Stewart AJ; Charlton P; Twentyman PR; Bevan P
    Br J Cancer; 1998 Oct; 78(7):885-92. PubMed ID: 9764579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The acridonecarboxamide GF120918 potently reverses P-glycoprotein-mediated resistance in human sarcoma MES-Dx5 cells.
    Traunecker HC; Stevens MC; Kerr DJ; Ferry DR
    Br J Cancer; 1999 Nov; 81(6):942-51. PubMed ID: 10576649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to the new anti-cancer phospholipid ilmofosine (BM 41 440).
    Hofmann J; Utz I; Spitaler M; Hofer S; Rybczynska M; Beck WT; Herrmann DB; Grunicke H
    Br J Cancer; 1997; 76(7):862-9. PubMed ID: 9328144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of cyclosporin and azidopine binding are associated with altered ATPase activity by a mutant P-glycoprotein with deleted phe(335).
    Chen KG; Lacayo NJ; Durán GE; Cohen D; Sikic BI
    Mol Pharmacol; 2000 Apr; 57(4):769-77. PubMed ID: 10727524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of P-glycoprotein activity by estramustine is limited by binding to plasma proteins.
    Smith CD; Zilfou JT; Zhang X; Hudes GR; Tew KD
    Cancer; 1995 May; 75(10):2597-604. PubMed ID: 7736407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BIBW22 BS, potent multidrug resistance-reversing agent, binds directly to P-glycoprotein and accumulates in drug-resistant cells.
    Liu Z; Lheureux F; Pouliot JF; Heckel A; Bamberger U; Georges E
    Mol Pharmacol; 1996 Sep; 50(3):482-92. PubMed ID: 8794885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.